中国P站

Antimicrobial stewardship (AMS) refers to a set of coordinated strategies aimed at promoting the appropriate use of antibiotics, antivirals, antifungals, and other antimicrobial agents. The primary goals are to optimize patient outcomes, reduce adverse effects, and curb the development of antimicrobial resistance (AMR). The emergence of multidrug-resistant organisms, fueled by inappropriate antimicrobial use, represents a critical global health threat. AMS programs are therefore essential in both hospital and community settings to ensure that these life-saving drugs remain effective for current and future generations [1,2].

Discussion

The principles of antimicrobial stewardship center on the judicious selection, dosing, route, and duration of antimicrobial therapy. Effective stewardship involves a multidisciplinary team, including infectious disease specialists, pharmacists, microbiologists, and infection control professionals. These teams monitor prescribing practices, implement evidence-based guidelines, and provide education to clinicians on rational antimicrobial use. Tools such as antibiotic “time-outs,” prospective audit and feedback, and formulary restrictions are commonly employed to guide appropriate prescribing [3,4].

AMS programs not only target the reduction of unnecessary or inappropriate antibiotic use but also emphasize optimizing therapy for patients who genuinely require treatment. This includes selecting narrow-spectrum agents whenever possible, tailoring therapy based on culture and sensitivity results, and adjusting dosing to maximize efficacy while minimizing toxicity. By doing so, AMS improves patient outcomes, reduces hospital length of stay, and lowers the risk of complications such as Clostridioides difficile infection [5-8].

The impact of AMS extends beyond individual patient care to public health. Overuse and misuse of antimicrobials drive the emergence and spread of resistant pathogens, complicating the treatment of infections and increasing healthcare costs. By promoting rational use, AMS programs slow the development of resistance, preserving the effectiveness of existing drugs. Furthermore, antimicrobial stewardship is closely linked to infection prevention strategies, including hand hygiene, vaccination, and environmental cleaning, creating a comprehensive approach to combatting AMR [9,10].

Global initiatives, such as those led by the World Health Organization (WHO), highlight the importance of implementing AMS at national and institutional levels. Guidelines encourage standardized monitoring, reporting of antimicrobial use, and integration of stewardship principles into medical education. Digital health technologies, including electronic prescribing systems and decision-support tools, have enhanced the ability of AMS programs to track antimicrobial consumption, identify patterns of inappropriate use, and deliver real-time guidance to clinicians.

Conclusion

Antimicrobial stewardship is a critical strategy to ensure the safe, effective, and sustainable use of antimicrobial agents. By optimizing prescribing practices, minimizing resistance, and improving patient outcomes, AMS programs safeguard both individual and public health. The integration of multidisciplinary teams, evidence-based guidelines, digital tools, and global collaboration enhances the effectiveness of stewardship initiatives. In an era of rising antimicrobial resistance, strengthening antimicrobial stewardship is not only a medical imperative but a societal necessity, ensuring that these vital drugs continue to save lives for generations to come.

References

1. Jian SW, Chen CM, Lee CY, Liu DP (2017) . Health Secur 15(2): 144-153.

   , ,

2. Thomas DR, Cann KF, Evans MR, Roderick J, Browning M, et al. (2011) . Int J STD AIDS 22: 488-492.

   , ,

3. Rotz LD, Hughes JM (2004) . Nat Med 10: 130-6.

   , ,

4. Gorman S (2013) Scand J Infect Dis 45: 944-947.

   , ,

5. Madoff LC, Woodall JP (2005) Arch Med Res 36: 724-730.

   , ,

6. Heymann DL (2004) Int J Infect Dis 8 Suppl 2: 15-20.

   , ,

7. Olson SH, Benedum CM, Mekaru SR, Preston ND, Mazet JA, et al. (2015) . Emerg Infect Dis 21: 1285-1292.

   , ,

8. Woodall JP (2001) . Cad Saude Publica 17: 147-154.

   , ,

9. Carrion M, Madoff LC (2017) . Int Health 9:177-183.

   , ,

10. Rathore MH, Runyon J, Haque TU (2017) 64: 2771.

    , ,